Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
NED Medical
AddedFeb 18, 2024
UpdatedJun 18, 2026
NED Medical

NED Medical

Seed

NED Medical: Revolutionizing oncology with curative-intent embolization equipment for unresectable tumors.

HQ
Norwell, MA, US
Founded
2022
Overview
Compare
Fundraising
Employees
Website

NED Medical, founded with a mission to revolutionize oncology treatment, focuses on manufacturing advanced embolization equipment aimed at transforming oncology embolization therapy from palliative to curative-intent. Their primary product line targets the treatment of unresectable tumors, particularly liver cancer, with the goal of significantly improving patient outcomes. The company is dedicated to addressing the critical need for better survival rates in liver cancer, which currently has a dismal 5-year survival rate of 15.6%.

Notable figures affiliated with NED Medical include leading oncologists and medical device experts who contribute to the development and refinement of their innovative technologies. The company has garnered attention from prominent investors in the healthcare sector, reflecting confidence in its potential impact. Key achievements include the development and successful deployment of their flagship product, CombiSphere, which has shown promise in clinical trials. Overall, NED Medical is making significant strides in the field of oncology, offering hope for improved treatment options for patients worldwide.

NED Medical - Similar Companies

Nectero Medical logo

Nectero Medical

necteromed.com

NED Biosystems logo

NED Biosystems

nedbiosystems.com

Nemedio logo

Nemedio

nemedio.com

Embolx logo

Embolx

embolx.com

Neurvana Medical logo

Neurvana Medical

EmboMedics logo

EmboMedics

Neurosonics Medical logo

Neurosonics Medical

NeuRx Medical logo

NeuRx Medical

neurxmed.com

NDI Medical logo

NDI Medical

ndimedical.com

EndoShunt Medical logo

EndoShunt Medical

endoshunt.com

Early Bird Medical logo

Early Bird Medical

earlybirdmed.com

NeuraMedica logo

NeuraMedica

Renata Medical logo

Renata Medical

renatamedical.com

Luminate Medical logo

Luminate Medical

luminatemed.com

Nexeon Medsystems logo

Nexeon Medsystems

nexeonmed.com

NED Medical - Quick Facts

Who are NED Medical's competitors?

Companies similar to NED Medical include Nectero Medical, NED Biosystems, Nemedio and Embolx.

When was NED Medical founded?

NED Medical was founded in 2022.

Where is NED Medical's headquarters located?

NED Medical's headquarters is located in Norwell, MA, US.

When was NED Medical's last funding round?

NED Medical's most recent funding round was for $500k (USD) in August 2023.

How much has NED Medical raised to-date?

As of Aug 28, 2023, NED Medical has raised a total of $500k (USD).

How many employees does NED Medical have?

NED Medical has 1 employee as of Feb 5, 2024.

NED Medical - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified